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Abstract.
Background: US studies suggest that leptin, a fat-derived hormone, may be protective against the development of dementia.
Objective: To investigate the complex relationship between leptin levels and cognitive decline in elderly Italians.
Methods:We studied circulating fasting leptin levels in 809 elderly adults free from dementia who participated in the prospective
Italian population-based InCHIANTI study between 1998 and 2009 (mean follow-up of 8.0 years). Global cognitive decline
was defined as a reduction of ≥5 points on the Mini-Mental State Examination (MMSE). Trail-Making Tests A and B were
also incorporated, with cognitive decline defined as discontinued testing or the worst 10% of change from baseline. We also
investigated whether any association could be explained by midlife weight and whether cognitive decline was associated with
changing leptin levels.
Results: The multivariate adjusted relative risk ([RR]; 95% confidence interval [CI]) of cognitive decline on the MMSE was
0.84 (95% CI 0.73–0.97) in relation to baseline sex-standardized log-leptin levels. High leptin levels showed a non-significant
trend toward a reduced risk of decline on the Trail-Making Tests A (RR = 0.85, 95% CI 0.71–1.02) and B (RR = 0.90, 0.79–1.02).
Adjusting for midlife weight or change in weight did not alter the pattern of results, and cognitive decline was not associated
with changing leptin levels.
Conclusions: High leptin levels were independently associated with a reduced risk of cognitive decline in elderly Italians.
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INTRODUCTION
Leptin is a fat-derived hormone which regulates
energy intake and expenditure via hypothalamic sig-
naling [1]. Evidence from in vivo and in vitro studies
suggest that leptin is also involved in memory forma-
tion and learning [2–4] and reduces the accumulation
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of amyloid- [5, 6] and phosphorylated tau deposits
[5], two pathological hallmarks of Alzheimer’s dis-
ease. Furthermore, leptin levels are significantly lower
in individuals with mild cognitive impairment and
Alzheimer’s disease compared to healthy controls [7].
Several recent prospective studies of elderly US adults
have found an association between high leptin levels
and a decreased risk of cognitive decline and dementia
[8–11]. Stratified analyses suggest that this association
may be strongest in non-obese elders [9–11], which
is hypothesized to reflect an acquired resistance to
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leptin’s neuroprotective effects in obesity [12]. How-
ever, no association between midlife leptin and late-life
dementia risk was observed in European women [13].
Further studies are therefore necessary to confirm
whether midlife and late-life leptin levels are associ-
ated with the risk of cognitive decline or dementia in
different populations. The possibility of reverse cau-
sation remains a key concern that has not been fully
addressed by previous studies. In short, early patho-
logical changes associated with dementia may lead to
weight loss and a reduction in circulating leptin lev-
els, which in turn may predict an increased risk of
subsequent cognitive decline [14].
We therefore investigated the association between
serum leptin levels and long-term cognitive decline
in a population-based cohort study of elderly Italians.
In a series of secondary analyses we also examined
whether any association was accounted for by midlife
body mass index (BMI), or whether serum leptin levels
were changing in participants experiencing cognitive
decline.
METHODS
Population
The Invecchiare in Chianti (InCHIANTI) study is a
population-based prospective cohort study located in
Greve in Chianti and Bagno a Ripoli, in Tuscany, Italy
and is described in detail elsewhere [15]. 1,270 indi-
viduals aged 65 years or older were randomly selected
from city registries and 1,155 agreed to participate.
We excluded 82 participants with dementia at base-
line as diagnosed by geriatricians and a psychologist
according to criteria set out in the Diagnostic and Sta-
tistical Manual of Mental Disorders (Fourth Edition).
Of these, 809 participants had valid baseline fasting
serum leptin and cognitive measurements as well as at
least one follow-up cognitive assessment conducted in
3 year intervals between 1998 and 2009 (mean [SD]
follow-up, 8.0 [2.3] years, median 9.0 years). Com-
pared with the analyzed group, those with missing
baseline data or lost to follow-up (n = 266) were older
(mean [SD] age, 77.8 [8] versus 73.7 [6.6] years old,
p < 0.001) and had lower MMSE scores (mean [SD]
score, 24 [3.9] versus 25.6 [2.9], p < 0.001). There was
no significant difference in serum leptin levels (mean
[SD] ng/ml, 13.9 [24] versus 13.6 [16.7], p = 0.86), and
participants were no more likely to be female (53.4%
versus 57.4%, p = 0.26) nor did they differ in years of
education (mean [SD], 5.2 [3.7] versus 5.5 [3.2] years,
p = 0.14).
Standard protocol approvals, registrations, and
patient consents
Ethical approval for the study was provided by the
Instituto Nazionale Riposo e Cura Anziani institu-
tional review board. Informed consent to participate
was obtained from participants or, if they could not
provide consent, a close relative was asked to provide
consent on their behalf.
Cognitive tests
The Mini-Mental State Examination (MMSE) and
Trail-Making Tests A and B (Trails A and B) were
administered at baseline and repeated at years 3, 6, and
9 of follow-up. The MMSE is a widely used screening
test for dementia and cognitive decline in the general
population that measures various aspects of cognitive
functioning including memory, concentration, visu-
ospatial skills, orientation, and language abilities [16].
Overall scores range from 0–30, with lower scores indi-
cating worse cognitive functioning. The Trails A and
B provide information about executive functioning,
visual search, visual attention, and motor speed [17].
Trails A requires individuals to draw a line between
25 numbers in a sequential order (1, 2, 3, etc.) while
Trails B alternates between numbers and letters (1,
A, 2, B, etc.). The former places greater emphasis on
attention, and the latter places more demand on exec-
utive function. Longer times, with a range from 0–300
seconds, indicate worse cognitive functioning. 675 par-
ticipants had at least one follow-up attempt at Trails A
and 551 participants had at least one follow-up attempt
at Trails B.
Leptin assay
Blood samples were obtained from fasting samples
in 1998–2000, 2001–2003, and 2004–2006 and were
frozen at −80◦C until analysis. Serum leptin levels
were determined using a multiplex assay kit (Human
Endocrine LINCOplex kit; Linco Research, Inc, St.
Charles, MO, USA) and the minimum detectable con-
centration was 1 ng/mL with an intra-assay coefficient
of variation of 5.1%. Further descriptive data regarding
leptin is provided in Supplementary Table 1.
Covariates
We adjusted for covariates that could potentially
confound the relationship between leptin and cog-
nitive decline [8, 9]. These included age in years,
sex, baseline cognitive score, number of years edu-
cation, depressive symptoms (≥16 on the Center for
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Table 1
Baseline characteristics of 809 participants stratified by sex-standardized log-leptin quartiles (ng/mL)
All Leptin quartiles p-value
(n = 809)
1 2 3 4
(n = 203) (n = 202) (n = 202) (n = 202)
Leptin ng/mL, mean (SD) 13.6 (16.7) 3.2 (2.1) 7.5 (3.5) 12.8 (6.0) 31.0 (24.9) <0.001
Females, No. (%) 464 (57.4) 116 (57.1) 116 (57.4) 116 (57.4) 116 (57.4) 1
Age in years, mean (SD) 73.7 (6.6) 75.4 (7.2) 73.6 (6.7) 72.4 (6.0) 73.5 (6.2) 0.01
Years in school, mean (SD) 5.5 (3.2) 5.4 (3.3) 5.6 (3.3) 5.6 (3.2) 5.4 (3.2) 0.8
CES-D depression score ≥16, 125/807 (15.5) 33/202 (16.3) 33/201 (16.4) 31 (15.4) 28 (13.9) 0.88
No./total (%)
Current cigarette smoker, 107 (13.2) 33 (16.3) 24 (11.9) 26 (12.8) 24 (11.9) 0.52
No. (%)
Stroke, No./total (%) 40/801 (5.0) 13/200 (6.5) 4/200 (2.0) 10/201 (5.0) 13/200 (6.5) 0.13
Cardiovascular disease, 115/801 (14.4) 29/200 (14.5) 28/200 (14.0) 28/201 (13.9) 30/200 (15.0) 0.99
No./total (%)
Hypertension, No./total (%) 626/801 (78.2) 158/200 (79.0) 151/200 (75.5) 155/201 (71.1) 162/200 (81.0) 0.58
Diabetes, No./total (%) 110/801 (13.7) 21/200 (10.5) 30/200 (15.0) 20/201 (10.0) 39/200 (19.5) 0.02
Cognitive scores, mean (SD)
MMSE 25.6 (2.9) 25.4 (3.2) 25.8 (2.9) 25.7 (2.9) 25.5 (2.7) 0.39
Trails A 94.6 (60.6) 104.4 (69.6) 88.9 (57.6) 88.9 (56.4) 96.7 (57.8) 0.06
Trails B 175.5 (75.8) 171.4 (71.2) 171.9 (74.3) 180.1 (78.7) 177.7 (78.3) 0.72
APOE-e4, No./total (%) 91/591 (15.4) 22/146 (15.1) 26/150 (17.3) 18/147 (12.2) 25 (16.9) 0.61
Late-life BMI, No./total (%) <0.001
<25 228/790 (28.9) 116/195 (59.5) 70/198 (33.4) 30/200 (15.0) 12/197 (6.1)
25-<30 364/790 (46.1) 67/195 (34.4) 99/198 (50.0) 118/200 (59.0) 80/197 (40.6)
≥30 198/790 (25.1) 12/195 (6.2) 29/198 (14.7) 52/200 (26.0) 105/197 (53.3)
Midlife BMI, No./total (%) <0.001
<25 256/709 (36.1) 84/178 (47.2) 69/177 (38.0) 57/182 (31.3) 46/172 (26.4)
25-<30 345/709 (48.7) 80/178 (44.9) 85/177 (48.0) 94/182 (51.7) 86/172 (50.0)
≥30 108/709 (15.2) 14/178 (7.9) 23/177 (13.0) 31/182 (17.0) 40/172 (23.3)
Waist-to-hip ratio, mean (SD) 0.92 (0.07) 0.90 (0.07) 0.92 (0.07) 0.92 (0.07) 0.93 (0.08) <0.001
Years of follow-up, mean (SD) 7.95 (2.29) 7.75 (2.32) 7.71 (2.58) 8.38 (1.91) 7.97 (2.25) 0.01
SD, standard deviation; n, number of participants; CES-D, Center for Epidemiologic Studies Depression Scale (score of 16 or greater indicates
evidence of depressive symptoms); MMSE, Mini-Mental Examination (range, 0–30, higher score represents better cognitive function); Trails
A, Trail-Making Test A; Trails B, Trail-Making Test B p-value – chi-square for categorical variables and ANOVA for continuous variables.
Epidemiologic Studies Depression Scale), smoking
status (current versus non/former smoker), stroke
(medical history, physical exam), cardiovascular dis-
ease (medical history of myocardial infarction, angina
pectoris, peripheral arterial disease, or atrial fibrillation
or right carotid stenosis ≥40% measured using carotid
ultrasound color Doppler examination), hypertension
(medical history, or systolic blood pressure ≥140
mmHg or diastolic blood pressure ≥90 mmHg, blood
pressure measured with standard mercury sphygmo-
manometer on three occasions with average of last
two measures used in analysis [18]), diabetes (med-
ical history, former or current anti-diabetic treatment,
blood glucose levels ≥126 mg/dL, glucose measured
using an enzymatic colorimetric assay [19]), APOE-4
(present or not present), BMI (groups of <25, 25-<30
and ≥30, calculated as weight in kilograms divided by
height in meters squared) and waist-to-hip ratio (cal-
culated as waist divided by hip in cm) and length of
follow-up in years.
Midlife BMI
At study baseline, participants had their height mea-
sured in cm and self-reported their estimated midlife
weight (age 50 years) in kg. This information was used
to derive midlife BMI (kg/m2). Change in BMI from
midlife to baseline was obtained by subtracting midlife
BMI from baseline BMI. This was then divided by
number of years between age 50 and age at baseline
to produce change in BMI from midlife to baseline
per year, hereafter referred to as change in BMI. Both
midlife BMI and change in BMI were entered into
analyses as continuous variables.
Statistical analyses
Leptin concentration was positively skewed in both
sexes with females having significantly higher lev-
els compared to males (mean [SD] ng/ml, 18.4 [19.5]
versus 7.2 [8.7], p < 0.001). The distribution of leptin
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was therefore normalized using a natural logarithm
transformation and then standardized within each sex
(mean [SD], 0 [1]). Normally distributed sex standard-
ized leptin was split by quartiles to test for associations
with baseline characteristics using analysis of vari-
ance for continuous variables and chi-squared test
for categorical variables. Multivariate logistic regres-
sion models were used to investigate the relationship
between baseline sex-standardized log-leptin levels
and substantial cognitive decline. Odds ratios were
converted to relative risk ratios using the method
developed by Zhang and Yu [20]. For the MMSE, sub-
stantial cognitive decline was defined as a decrease
of 5 points or more from baseline assessment to any
stage of follow-up (n = 221 decliners) [21]. For Trails
A (n = 144 decliners) and Trails B (n = 304 decliners),
substantial cognitive decline was defined as being in
the worst 10% of change from baseline to last follow-
up, or having testing discontinued at last follow-up due
to multiple mistakes [22]. There was no evidence of
overfitting or collinearity.
The functional form of the relationship between
the log odds of cognitive decline on the MMSE
and a smoothing spline plot of sex-standardized log-
leptin levels was explored using generalized additive
models with smoothing splines [23]. This approach
provides a method of identifying departures from lin-
earity in exposure-response relationships. Linearity
was assessed by visual inspection of the estimated
spline functions and by consideration of the “estimated
degrees of freedom” for the smoothed terms where
values close to 1 were taken as evidence of linearity.
In additional sensitivity analyses we excluded indi-
viduals aged over 75 years and with an MMSE score
<24 at baseline to examine whether there was an asso-
ciation in younger individuals with normal cognitive
functioning. To investigate possible effect modification
on the basis of body composition, we added interaction
terms for leptin X obesity as well as leptin X waist-to-
hip ratio into the regression models and then performed
stratified analysis by BMI groups of normal weight
(<25), overweight (≥25-<30), and obese (≥30) and
waist-to-hip ratio (lowest 75% and highest 25%).
In order to investigate the possibility of reverse
causation we performed a series of secondary analy-
ses. We repeated the main logistic regression analyses
adjusting for BMI at 50 years of age and change in
BMI per year from 50 years of age to baseline. We
also used a mixed-effects model to investigate differ-
ences in sex-standardized log-leptin trajectories from
baseline to follow-up measurements at 3 and 6 years
between participants who declined and did not decline
substantially on the MMSE. Correlations between
successive measurements on the same individual were
accounted for using parametric models for covariance
structure in longitudinal data [24]. Group differences
in leptin trajectory were assessed through inclusion
of interaction terms between waves of follow-up and
cognitive decline group. In an additional analysis, a
lagged mixed-effects model was used to investigate
whether leptin levels at waves 3 and 6 were asso-
ciated with MMSE score at baseline and wave 3,
respectively. The model was fully adjusted for poten-
tial confounders as well as leptin levels at the previous
wave. A mixed-effects model was also used to investi-
gate BMI trajectories in participants who declined and
did not decline substantially on the MMSE. P-values
were two-sided throughout and statistical significance
was preset at 0.05. All analyses were performed
using Stata/SE version 12.1 (StataCorp, College Sta-
tion, Texas) with the exception of the spline plot and
the leptin and BMI trajectories mixed-effects models
which were fitted in R version 2.15.1 (http://www.r-
project.org).
RESULTS
Baseline characteristics for participants are provided
in Table 1. Significant differences between partici-
pants across leptin quartiles were observed for age,
where those in the lowest leptin quartile were around
two years older than those in quartiles 2–4. Inconsis-
tent differences between quartiles were observed for
diabetes and years of follow-up. Measures of waist-to-
hip ratio and BMI at midlife and late-life increased
across leptin quartiles. No differences across leptin
quartiles were observed for sex, education in years,
depressive symptoms, current smoking status, stroke,
cardiovascular disease, hypertension, cognitive scores,
or APOE-4 haplotype. Sex-standardized log-leptin
levels were highly correlated across waves (baseline
to year 3, r = 0.64, baseline to year 6, r = 0.60 and year
3 to year 6, r = 0.71).
In basic models adjusted for age, sex, and baseline
cognition high leptin levels were significantly associ-
ated with a reduced risk of global cognitive decline on
the MMSE (Table 2). High leptin was also associated
with a reduced risk of cognitive decline on the Trails A
and Trails B although this trend did not reach statistical
significance. After additional adjustment for major
risk factors for cognitive decline, the associations
remained highly similar to the minimally adjusted
models. The multivariate adjusted relative risk (95%
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Table 2
Relative risk of substantial cognitive decline by sex-standardized log-leptin levelsa
Measure of substantial cognitive declineb n RR (95% CI) p-value
MMSE
Model A: Age, sex and baseline 809 0.85 (0.74–0.97) 0.02
cognitive score adjusted
Model B: Model A plus major risk 799 0.84 (0.73–0.97) 0.01
factors for cognitive declinec
Model C: Model B plus APOE-4, 569 0.73 (0.59–0.90) 0.003
BMI and waist-to-hip ratio
Trails A
Model A: Age, sex and baseline 675 0.85 (0.71–1.01) 0.06
cognitive score adjusted
Model B: Model A plus major risk 673 0.85 (0.71–1.02) 0.08
factors for cognitive declinec
Model C: Model B plus APOE-4, 484 0.75 (0.57–0.98) 0.03
BMI and waist-to-hip ratio
Trails B
Model A: Age, sex and baseline 551 0.89 (0.78–1.01) 0.07
cognitive score adjusted
Model B: Model A plus major risk 551 0.90 (0.79–1.02) 0.11
factors for cognitive declinec
Model C: Model B plus APOE-4, 399 0.84 (0.69–1.00) 0.05
BMI and waist-to-hip ratio
RR, relative risk ratio; CI, confidence interval. aLeptin was normalized using a natural logarithm transformation and
then standardized within each sex (mean [SD], 0 [1]). bSubstantial cognitive decline defined as a drop of 5 points or
more on the MMSE (range, 0–30, higher score represents better function) and the worst 10% of cognitive change
or test discontinued for the Trails A and B. cAdjusted for Model A and years in school, depressive symptoms,
smoking, stroke, cardiovascular disease, hypertension, diabetes, and length of follow-up.
Fig. 1. Smoothing spline plot of sex-standardized log-leptin levels
versus change in log odds of cognitive decline on the Mini-Mental
State Examinationa,b. aLeptin was normalized using a natural loga-
rithm transformation and then standardized within each sex (mean
[SD], 0 [1]). bAdjusted for age, sex, baseline cognitive score, years in
school, depressive symptoms, smoking, stroke, cardiovascular dis-
ease, hypertension, diabetes, and length of follow-up. Substantial
cognitive decline defined as a drop of 5 points or more on the MMSE
(range, 0–30, higher score represents better function).
confidence interval [CI]) of cognitive decline on the
MMSE was 0.84 (95% CI 0.73–0.97) in relation to
sex-standardized log-leptin levels. High leptin
remained associated with a lower risk of cogni-
tive decline on the Trails A and Trails B in fully
adjusted models, although again these trends were
not statistically significant. Furthermore, the pattern
of associations was not altered when adjusting for
additional covariates; APOE-4, BMI, and waist-to-
hip ratio, although the trend for Trails A and Trails
B became statistically significant (Table 2). Fig. 1
further illustrates how higher leptin levels are linked
with lower odds of global cognitive decline.
When excluding those aged over 75 years and with
a baseline MMSE score <24, the association between
leptin and decline on the MMSE was highly simi-
lar to the main findings (n = 458, RR = 0.79, 95% CI
0.62–1.00, p = 0.05).
When including interaction terms in the main anal-
yses, no significant leptin X obesity interactions were
observed (MMSE p = 0.19; Trails A p = 0.78; Trail-
Making Test B p = 0.47). There was a significant
leptin X waist-to-hip ratio interaction for the MMSE
(p = 0.03), but not the Trails A (p = 0.21) or Trails B
(p = 0.81). High leptin was associated with a lower
risk of cognitive decline on the MMSE and Trails A
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Table 3
Relative risk of substantial cognitive decline by sex-standardized log-leptin levels adjusted for midlife BMIa
Measure of substantial Adjusted for BMI Adjusted for change
cognitive declineb at 50 years old in BMI from 50 years
old to baseline
n RR (95% CI) p-value RR (95% CI) p-value
MMSEc 709 0.78 (0.66–0.92) 0.002 0.82 (0.69–0.97) 0.02
Trails Ac 611 0.85 (0.69–1.03) 0.1 0.84 (0.68–1.03) 0.09
Trails Bc 507 0.88 (0.76–1.01) 0.08 0.89 (0.76–1.02) 0.09
RR, relative risk ratio; CI, confidence interval; BMI, body mass index. aLeptin was normalized using a natural
logarithm transformation and then standardized within each sex (mean [SD], 0 [1]). bSubstantial cognitive decline
defined as a drop of 5 points or more on the MMSE (range, 0–30, higher score represents better function) and the
worst 10% of cognitive change or test discontinued for the Trails A and B. cAdjusted for age, sex, baseline cognitive
score, years in school, depressive symptoms, smoking, stroke, cardiovascular disease, hypertension, diabetes and
length of follow-up.
Fig. 2. Mixed effects model of change in sex-standardized log-leptin
levels over 6 years by cognitive decliners and cognitive non-decliners
on the Mini-Mental State Examinationa,b,c. aLeptin was normal-
ized using a natural logarithm transformation and then standardized
within each sex (mean [SD], 0 [1]). bAdjusted for age, sex, baseline
cognitive score, years in school, depressive symptoms, smoking,
stroke, cardiovascular disease, hypertension, diabetes, and length of
follow-up. Substantial cognitive decline defined as a drop of 5 points
or more on the MMSE (range, 0–30, higher score represents better
function). cCognitive non-decliners, n = 584; Cognitive decliners,
n = 215.
and B when analyses were restricted to overweight
participants (BMI ≥25-<30), and the MMSE when
restricted to those in the lowest three quartiles of waist-
to-hip ratio (Supplementary Table 2). There were no
significant associations between leptin levels and cog-
nitive decline in normal weight or obese participants
or those in the highest waist-to-hip ratio quartile.
Additional adjustment for midlife BMI or change
in BMI from midlife to baseline made little difference
to the pattern of associations (Table 3). For example,
after adjustment for BMI at 50 years of age, the rela-
tive risk of cognitive decline on the MMSE was 0.78
(95% CI 0.66–0.92). A mixed-effects model found that
the trajectories of serum leptin between baseline and
follow-up did not differ significantly between partic-
ipants who declined substantially on the MMSE and
those who did not (p = 0.34, Fig. 2). Additionally, a
lagged mixed-effects model found that leptin levels at
wave 3 and 6 were not associated with MMSE score
at baseline or wave 3 (= −0.01, 95% CI −0.03–0.00,
p = 0.10). A further mixed-effects analysis found that
BMI declined significantly more between baseline and
follow-up in participants who declined on the MMSE
compared to those who did not (p = 0.002).
DISCUSSION
In an Italian prospective population-based cohort
study of elderly dementia-free adults, higher leptin
levels at baseline were associated with a lower risk
of global cognitive decline. This association remained
after adjustment for potential confounders includ-
ing demographic variables and vascular risk factors.
Adjustment for midlife BMI or change in BMI did
not account for the association, and cognitive decline
did not predict subsequent changes in circulating
leptin, reducing the likelihood of reverse causation.
Conversely, cognitive decline predicted significant
decrease in BMI throughout follow-up as expected
[14]. Excluding over 75 year olds with low cogni-
tive function at baseline did not change the pattern
of results. Stratification on the basis of body compo-
sition revealed that the association was strongest in
overweight participants.
Our findings are consistent with recent prospective
studies conducted in elderly adults in the US that have
found an association between high leptin levels and a
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reduced risk of cognitive decline and dementia [8–11].
Our study is the first to demonstrate that the associa-
tion is found in a non-US population despite a different
pattern of potential confounders. Previous studies were
also unable to take into account midlife body compo-
sition and did not incorporate multiple measures of
circulating leptin to address the possibility of reverse
causation.
One study observed significant interactions between
obesity and waist-to-hip ratio and all-cause demen-
tia; with high leptin associated with a lower risk of
dementia in the non-obese and those in the lowest three
quartiles of waist-to-hip ratio [9]. Similarly, another
study found higher leptin associated with a lower risk
of cognitive decline in adults with a small waist circum-
ference but no association in those with a large waist
circumference [10]. However, a different study found
that high leptin levels were associated with a reduced
dementia risk in normal weight elderly women, but
there was no association in those overweight or obese
[11]. Our results suggest that the association may be
strongest in overweight elderly adults, though there
was no interaction between leptin and obesity for any of
the cognitive measures. There was evidence for possi-
ble effect modification by waist-to-hip ratio for global
cognitive decline, but not for attention or executive
function. Despite methodological differences, there is
little evidence for an association between leptin and
dementia-related outcomes in elderly adults who are
obese or have a large waist circumference. This is
hypothesized to reflect an acquired resistance to the
central effects of leptin, though this remains poorly
understood [25–27]. Given the inconsistent findings
for normal weight and overweight elderly adults, fur-
ther research is needed to address this.
While late-life leptin levels seem to be associated
with dementia risk, there was no evidence for an
association between midlife leptin levels and late-life
dementia risk in Swedish women followed for 31 to 35
years [13]. This raises the possibility that reverse cau-
sation leads to an association between late-life leptin
and dementia-related outcomes due to declining leptin
levels and weight loss linked with neuropathological
changes [14], or that midlife leptin levels are a poor
indicator of overall leptin levels during follow-up or
late-life leptin levels due to regression dilution bias
[28]. Our results make the former less likely by demon-
strating that the associations observed in late-life are
not accounted for by midlife BMI or change in BMI.
Furthermore leptin levels were stable in older adults
who experienced substantial cognitive decline, again
making reverse causation less likely.
Cellular and animal research provides compelling
evidence that leptin has multiple neuroprotective
effects. Leptin was found to facilitate hippocampal
synaptic plasticity via NMDA receptors in rats, which
are necessary for the induction of long-term poten-
tiation [3]. Leptin increases motility and density of
dendritic filopodia in hippocampal neurons which is
associated with a rapid increase in the formation
of hippocampal synaptic connections [29]. Rodents
with leptin receptor deficiency in the hippocampus
demonstrate poor spatial memory and impaired long
term potentiation [30]. Direct injection of leptin into
the hippocampus improves memory performance in a
transgenic animal model of Alzheimer’s disease [2].
Leptin reduces the accumulation of the Alzheimer’s
disease hallmarks amyloid- [5, 6] and phosphorylated
tau [5]. Furthermore leptin may reduce both hallmarks
through AMPK and sirtuin pathways as well as the
inhibition of glycogen synthase kinase-3 [31–34].
Our study had a number of strengths; to our knowl-
edge this is the first study outside of the US to
investigate the association between late-life leptin lev-
els and cognitive decline. The sample is a reasonably
large population-based sample, and attrition during
follow-up was low. It is the first study to adjust for
midlife weight and to examine changes in late-life
leptin levels in relation to cognitive decline. These
analyses allowed us to address the possibility of reverse
causation in a more robust way than has previously
been possible. We restricted our analyses to those with
high levels of cognitive function at baseline which did
not alter the pattern of associations. Our study had
a number of limitations. The InCHIANTI cohort is
limited to participants of elderly white individuals,
so our findings may not generalize to other popula-
tions. Statistical power for Trails A and B analyses
was comparatively limited due to the smaller num-
ber of participants who completed these tests. Midlife
BMI was derived from midlife weight by self-report
and height measured at baseline and is therefore less
accurate than if BMI was measured directly at midlife.
As with all observational studies, unmeasured con-
founding remains a possibility, and our findings do not
establish a causal relationship.
We found that high serum leptin levels were prospec-
tively associated with a reduced risk of global cognitive
decline in elderly Italians. This association remained
significant in models fully adjusted for a variety of
potential confounders. This is the first study to con-
firm that recent findings from the US generalize to
another population [8–11]. Adjustment for midlife
weight did not change the pattern of associations, and
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leptin levels were stable in those experiencing cog-
nitive decline making reverse causation less likely.
Further studies are therefore warranted to investi-
gate whether leptin has relevance to the prevention or
treatment of Alzheimer’s disease and other dementia
subtypes.
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